Is there a future for Trop-2-targeted ADCs in urothelial carcinoma? [0.03%]
靶向Trop-2的抗体药物偶联物在尿路上皮癌中未来可期吗？
S Coca Membribes,T Powles
S Coca Membribes
Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649 [0.03%]
纳武利尤单抗联合化疗作为晚期胃癌、胃食管结合部癌和食管腺癌一线治疗的5年随访结果：CheckMate 649研究
Y Y Janjigian,K Shitara,J A Ajani et al.
Y Y Janjigian et al.
Background: We report efficacy and safety results from the CheckMate 649 trial after 5 years of follow-up. Patients and methods: Adults...
Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up [0.03%]
前列腺癌（转移性和晚期）：诊断、治疗及随访欧洲肿瘤内科学会临床实践指南
K Fizazi,G Attard,A A Azad et al.
K Fizazi et al.
Pan-tumor harmonization of pathologic response assessment for standardized data collection in neoadjuvant trials (PATHdata): Results of a Society for Immunotherapy of Cancer multi-institutional reproducibility study [0.03%]
病理反应评估的泛肿瘤标准化数据收集方案（PATHdata）：一项国际免疫学会联盟多中心再现性研究结果
J S Deutsch,T R Cottrell,K Y Chen et al.
J S Deutsch et al.
Background: Pathologic response is an emerging surrogate marker for therapeutic efficacy and long-term patient outcomes. Updated guidelines for pan-tumor pathologic response assessment have recently been adopted for ongoi...
Progress in Targeting the Untouchables: Emerging Approaches for Hard-to-Drug Cancer Targets [0.03%]
难药物靶点癌症治疗的新兴方法学研究进展
N Coleman,H Tan,J R Ahnert
N Coleman
Innovation in drug development is an evolving concept that can take many forms, and is often confused with iteration, i.e., new versions of existing drug classes targeting familiar oncogenes. Yet meaningful innovation increasingly lies in t...
F C Maluf,K Martins da Trindade
F C Maluf
Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, for patients with EGFR-mutated NSCLC: Pooled analysis of phase 1 and phase 2 trials [0.03%]
针对EGFR突变型非小细胞肺癌患者的Iza-bren（BL-B01D1）：一种新型EGFR-HER3双特异性抗体偶联药物的1期和2期临床试验汇总分析
S-D Hong,Y-S Wang,H-Y Zhao et al.
S-D Hong et al.
Background: Therapeutic options after progression on EGFR tyrosine kinase inhibitors (TKIs) remain limited for patients with EGFR-mutated non-small cell lung cancer (NSCLC). Izalontamab brengitecan (Iza-bren; BL-B01D1) is...
Mechanisms of Clinical Resistance to Selective FGFR2 Inhibition by Lirafugratinib [0.03%]
Lirafugratinib选择性FGFR2抑制的临床抗性机制
H Ellis,E R Balasooriya,A Varkaris et al.
H Ellis et al.
Background: Pan-FGFR inhibitors, targeting FGFR1-3 or FGFR1-4, are FDA-approved for FGFR2-driven cholangiocarcinoma. However, acquired resistance and dose-limiting toxicities from systemic FGFR inhibition constrain effica...